Reaction
Nail Dystrophy reporting signals
As of the last recalculation, Nail Dystrophy appears in 548 FAERS reports alongside 12 co-occurring drug terms. The strongest observed disproportionality signal is ADO-TRASTUZUMAB EMTANSINE (PRR 93.5).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ado-Trastuzumab Emtansine | 20 | 93.5 | 93.7 |
| Pertuzumab | 48 | 73.4 | 73.5 |
| Terbinafine Hydrochloride | 13 | 56.9 | 57.0 |
| Exemestane | 22 | 40.6 | 40.6 |
| Trastuzumab | 61 | 37.9 | 37.9 |
| Docetaxel Anhydrous | 54 | 33.7 | 33.7 |
| Docetaxel | 54 | 33.6 | 33.7 |
| Midazolam | 17 | 26.4 | 26.4 |
| Letrozole Tablets | 26 | 21.5 | 21.5 |
| Paclitaxel (Aibumin-Bound) | 38 | 18.8 | 18.8 |
| Cetuximab | 14 | 17.4 | 17.4 |
| Paclitaxel | 42 | 17.4 | 17.4 |